renal failure requiring short-term dialysis post transplantation. Long-term complications included biliary anastomotic stricture in 6 (31%) patients and vascular complications in 3 (2 hepatic artery thrombosis, 1 hepatic vein stenting). One patient acquired hepatitis B from the transplanted liver. Reasons for re-transplantation were hepatic artery thrombosis (2), recurrent cirrhosis with portal hypertension (1) and primary non-function of the graft (1). Seven (35%) transplants had cirrhosis confirmed on biopsy (5) or clinically (ascites (1) or oesophageal varices (1)) at a mean time of 25.6 months post transplant (range 12–48 months). Five-year mortality in the cohort was 25%.

Conclusion Hepatitis C accounted for <10% of OLT episodes in Northern Ireland during the study period. This demand may increase in the future as the chronic complications of previously undiagnosed hepatitis C are seen. One third of this small cohort developed cirrhosis within a few years of OLT.

Competing interests None declared.

Introduction HEV is an emerging infection in developed countries, and is considered a porcine zoonosis. HEV has been found in pigs worldwide and a number of water courses. In most cases the route of infection remains uncertain. A previous UK study showed that HEV was associated geographically to pig farms and coastal areas.1 AIM: To study the geographical, environmental and social factors in HEV infection.

Methods Cases of HEV and controls were identified from 2147 consecutive patients attending the Jaundice Hotline clinic, Cornwall (1999–2011). For each case and control the following were recorded: e HBV (HBV DNA >20 000 IU/ml, ALT >40), 60% were inactive carriers (HBV DNA negative and 79% anti-HBe positive. 85% had HBV DNA checked for HBeAg/Ab status: 15% were HBeAg positive, 85% HBeAg negative and 79% anti-HBe positive. 85% had HBV DNA checked during the pregnancy. 9% had active HBeAg positive cHBV (HBV DNA >20 000 IU/ml, ALT >40), 5% had active HBeAg negative cHBV (HBV DNA >2000 and ALT >40), 9% were immunotolerant (HBeAg positive, ALT <40), 60% were inactive carriers (HBV DNA <2000 and ALT <40) and 19% were indeterminate. 13% of mothers had a HBV DNA >107 IU/ml, but only two patients were treated with tenofovir in the 3rd trimester. Of the eight patients with active HBV, six were successfully treated post-partum with oral antivirals/PEG-Interferon and two became inactive. 20% of inactive carriers experienced a post-partum flare in ALT that settled spontaneously.

Conclusion A high proportion of HBV infected mothers were born overseas; >1 in 6 had active cHBV or HBV DNA >107 IU/ml and were eligible for treatment to reduce the vertical transmission risk and/or prevent disease progression. All HBV infected mothers should be assessed for treatment and efforts to improve attendance at clinic appointments need to be intensified.

Competing interests None declared.

REFERENCE

PMO-162 PREGNANT MOTHERS WITH CHRONIC HEPATITIS B (HBV): HOW OFTEN IS TREATMENT NEEDED?

1Dyson,* 2E Michael, 2A Turley, 3S Moses, 4M Valappl, 4K Hudson, 4M Bassendine, 4S McPherson. 1Northern Deanery, Newcastle University, Newcastle, UK; 2Obstetrics, Newcastle upon Tyne NHS Trust, Newcastle University, Newcastle, UK; 3HPA, Newcastle University, Newcastle, UK; 4Liver Unit, Freeman Hospital, Newcastle University, Newcastle, UK; 5Institute of Cellular Medicine, Newcastle University, Newcastle, UK

Introduction HBV is a common cause of chronic liver disease worldwide. Vertical transmission is the commonest mode of infection. Since 2000 antenatal HBV screening is offered to all pregnant women in the UK. The British Viral Hepatitis Group recommend treating mothers with an HBV DNA level of >107 IU/ml with antivirals in the 3rd trimester to reduce the transmission risk. Few studies have evaluated the epidemiology/management of pregnant patients with HBV in the UK. We reviewed the management of mothers with HBV attending our obstetric services.

Methods Retrospective notes review of all HBV positive mothers who attended the obstetric service from January 07 to November 11. Data were collected on patient demographics, viral serology, HBV DNA and ALT levels and HBV management during their first pregnancy in the time period.

Results 81 HBsAg positive mothers (median age 28, 18–44) had 113 pregnancies in the study period. 96% were referred to the viral hepatitis service; however 28% of women did not attend >1 appointment. The mothers were born in 28 countries, most commonly China (30%) followed by countries in Eastern Europe (17%), Africa (16%), South Asia (16%) and elsewhere (21%). 29% were known to have chronic HBV (cHBV). All mothers were tested for HBeAg/Ab status: 15% were HBeAg positive, 85% HBeAg negative and 79% anti-HBe positive. 85% had HBV DNA checked during the pregnancy. 9% had active HBeAg positive cHBV (HBV DNA >20 000 IU/ml, ALT >40), 5% had active HBeAg negative cHBV (HBV DNA >2000 and ALT >40), 9% were immunotolerant (HBeAg positive, ALT <40), 60% were inactive carriers (HBV DNA <2000 and ALT <40) and 19% were indeterminate. 13% of mothers had a HBV DNA >107 IU/ml, but only two patients were treated with tenofovir in the 3rd trimester. Of the eight patients with active HBV, six were successfully treated post-partum with oral antivirals/PEG-Interferon and two became inactive. 20% of inactive carriers experienced a post-partum flare in ALT that settled spontaneously.

Conclusion A high proportion of HBV infected mothers were born overseas; >1 in 6 had active cHBV or HBV DNA >107 IU/ml and were eligible for treatment to reduce the vertical transmission risk and/or prevent disease progression. All HBV infected mothers should be assessed for treatment and efforts to improve attendance at clinic appointments need to be intensified.

Competing interests None declared.

PMO-161 HEPATITIS E (HEV) IN SOUTH WEST ENGLAND. GEOGRAPHICAL, ENVIRONMENTAL AND SOCIAL FACTORS: A CASE CONTROL STUDY

1J Hunter,* 2R Madden, 3A Stone, 4N Osborne, 5B Wheeler, 6M Barlow, 1R Bendall, 1N Lin, W Henley, W Gaze, H Dalton. 1European Centre for Environment & Human Health, Peninsula College of Medicine and Dentistry; 2Universities of Exeter and Plymouth, Truro; 3Health Protection Agency, St Austell; 4Centre for Health and Environmental Statistics, University of Plymouth, Plymouth, UK

Introduction HEV is an emerging infection in developed countries, and is considered a porcine zoonosis. HEV has been found in pigs worldwide and a number of water courses. In most cases the route of infection remains uncertain. A previous UK study showed that HEV was associated geographically to pig farms and coastal areas.1 AIM: To study the geographical, environmental and social factors in HEV infection.

Methods Cases of HEV and controls were identified from 2147 consecutive patients attending the Jaundice Hotline clinic, Cornwall (1999–2011). For each case and control the following were recorded: e HBV (HBV DNA >20 000 IU/ml, ALT >40), 60% were inactive carriers (HBV DNA negative and 79% anti-HBe positive. 85% had HBV DNA checked during the pregnancy. 9% had active HBeAg positive cHBV (HBV DNA >20 000 IU/ml, ALT >40), 5% had active HBeAg negative cHBV (HBV DNA >2000 and ALT >40), 9% were immunotolerant (HBeAg positive, ALT <40), 60% were inactive carriers (HBV DNA <2000 and ALT <40) and 19% were indeterminate. 13% of mothers had a HBV DNA >107 IU/ml, but only two patients were treated with tenofovir in the 3rd trimester. Of the eight patients with active HBV, six were successfully treated post-partum with oral antivirals/PEG-Interferon and two became inactive. 20% of inactive carriers experienced a post-partum flare in ALT that settled spontaneously.

Conclusion A high proportion of HBV infected mothers were born overseas; >1 in 6 had active cHBV or HBV DNA >107 IU/ml and were eligible for treatment to reduce the vertical transmission risk and/or prevent disease progression. All HBV infected mothers should be assessed for treatment and efforts to improve attendance at clinic appointments need to be intensified.

Competing interests None declared.